Houston Lung Symposium, April 28-29, 2012
Combining Houston Society of Clinical Pathologists Spring Seminar and The Methodist Hospital
Department of Pathology and Genomic Medicine Advances in Lung Cancer Seminar
Registration: http://houstonpathologists.org/upcomingevents.html
Philip T. Cagle, MD
Program Director
Saturday, April 28, 2012
Houston Society of Clinical Pathologists: Diagnostic Pulmonary Pathology
Alain Borczuk,MD, Department of Pathology and Cell Biology, Columbia University Medical
Center
“Benign Tumors and Tumor-Like Conditions of the Lung”
Lucian Chirieac, MD, Brigham and Women’s Hospital, Harvard Medical School
“Update on Mesothelioma”
Andrew Churg, MD, Chair, United States-Canadian Mesothelioma Reference Panel, University of
British Columbia, Canada
“Separation of Benign versus Malignant Mesothelial Proliferations”
Thomas Colby, MD, Chair, Dept of Laboratory Medicine and Pathology, Mayo Clinic Arizona
“Update on Idiopathic Interstitial Pneumonias”
Sanja Dacic, MD, PhD , University of Pittsburgh Medical Center, Deputy Editor-in-Chief, Archives
of Pathology & Laboratory Medicine
“Dilemmas in Lung Cancer Staging”
Kevin Leslie, MD, Dept of Laboratory Medicine and Pathology, Mayo Clinic Arizona
"Pulmonary Pathology of the Rheumatic Diseases"
Keith Kerr, MD, Aberdeen Royal Infirmary, Aberdeen University Medical School, Scotland, UK
“Proposed New Classification of Lung Cancer”
Jeffrey Myers, MD, Director, Division of Anatomic Pathology, University of Michigan
“The Changing Role of Pathology in Managing Patients with Unexplained Diffuse Lung Disease”
Sunday, April 29, 2012
The Methodist Hospital Department of Pathology and Laboratory Medicine Advances in Lung
Cancer Seminar
Yung-Jue Bang, M.D., Ph.D., Professor of Medical Oncology, Chairman, Department of Internal
Medicine, Seoul National University College of Medicine, Director, Clinical Trials Center, Seoul
National University Hospital, Seoul, KOREA
“Treatment of ALK-positive NSCLC”
Paul Bunn, MD, Executive Director, International Association for the Study of Lung Cancer,
James Dudley Chair in Cancer Research , University of Colorado, Denver, Director of the
University of Colorado Comprehensive Cancer Center
Keynote Speaker: “Worldwide Overview of the Current status of Lung Cancer Diagnosis and
Treatment “
Lida Hariri, MD, PhD, Massachusetts General Hospital, Harvard Medical School
“Volumetric Optical Frequency Domain Imaging of Lung Pathology: Improving Biopsy Sampling
and Evaluation”
Jürgen Hetzel, MD, Department of Medicine, University of Tuebingen, Germany
“Cryobiopsy in Pulmonary Diseases”
Pasi A. Jänne, MD, PhD, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute,
Harvard Medical School
“Strategies to overcome resistance to EGFR target therapies”
James Jett, MD, Editor-in-Chief, Journal of Thoracic Oncology, Division of Oncology, National
Jewish Health, Denver, CO
“Screening for Lung Cancer: Who should be screened?”
Marc Ladanyi, MD, The William Ruane Chair in Molecular Oncology Attending Pathologist,
Molecular Diagnostics Service Member, Human Oncology and Pathogenesis Program Memorial
Sloan-Kettering Cancer Center New York, NY
"Clinical genotyping of lung cancer: beyond EGFR and EML4-ALK, beyond adenocarcinoma"
Neal I. Lindeman, MD, Molecular Diagnostics at Brigham & Women’s Hospital, Harvard Medical
School
“EGFR, ALK, and KRAS Molecular Testing in Lung Adenocarcinoma: Why, When, and How”
Laura MacConaill, PhD, Scientific Director for the Center for Cancer Genome Discovery,
Personalized Cancer Medicine Partnership, Dana Farber Cancer Institute & Brigham and
Women's Hospital, Senior Scientist, Harvard Medical School
“Advancing Personalized Cancer Medicine in Lung Cancer."
Ignacio Wistuba, MD, Department of Pathology, M.D. Anderson Cancer Center
“Molecular Pathology of Lung Cancer: Changes in Prevention and Therapy Paradigms”
Steve Wong, PhD, PE Chairman, Department of Systems Medicine and Bioengineering; Director,
NCI Center for Modeling Cancer Development; John S Dunn Distinguished Endowed Chair in
Biomedical Engineering; Chief of Medical Physics and Chief Research Information Officer, The
Methodist Hospital System
“Lung Cancer Differential Diagnosis by Label-free, Molecular Vibrational Imaging”
Maureen Zakowski, MD, Director, Cytopathology Fellowship Program, Memorial Sloan Kettering
Cancer Center
“Role of Cytopathology in the Molecular Diagnostics and Targeted Therapy of Lung Cancer”